CR Pharma will be responsible for China clinical trials and other regulatory matters.
February 6, 2018 -- CR Pharma acquired China rights to a long-acting treatment for prostate cancer developed by Sweden’s Xbrane Biopharma. Spherotide is triptorelin, a GnRH analogue, in a parenteral depot formulation. CR Pharma will pay an initial license fee (described as a high single-digit million dollar amount) and unspecified milestones through China market authorization. Xbrane will supply the product while CR Pharma will be responsible for China clinical trials and other regulatory matters.
